

Limited Submission Funding Opportunities – updated 7/23/21

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Optional) – NEW!

<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-025.html>

MGH LOI Deadline: 8/09/21

NIH LOI Deadline: 8/24/21

NIH Application Deadline: 9/24/21

The purpose of the FIRST Cohort is to transform culture at NIH-funded extramural institutions by building a self-reinforcing community of scientists committed to diversity and inclusive excellence (defined below). Implementing and sustaining cultures of inclusive excellence within the program has the potential to be transformational for biomedical research at the awardee institutions and beyond. This community will be built through recruitment of faculty who are competitive for an advertised

Limited Submission Funding Opportunities – updated 7/23/21

research tenure-track or equivalent faculty position (positions must be at the Assistant Professor (or equivalent) level), have not held a position at this level, and have demonstrated strong commitment to promoting diversity and inclusive excellence.

2. Centers for HIV Structural Biology (U54 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-030.html>

MGH LOI Deadline: 8/16/21

NIH LOI Deadline: 9/13/21

NIH Application Deadline: 10/13/21

The purpose of this Funding Opportunity Announcement (FOA) is to support dynamic, multidisciplinary consortia of structural biologists, virologists, and computational scientists to resolve complex biological structures relevant to HIV prevention, treatment, and cure. The consortia are expected to leverage common resources, facilitate new collaborations, and engage and support the next generation of HIV structural biology researchers.